PHARMACOECONOMIC ANALYSIS OF THE IMPACT ON THE BUDGET COSTS OF ADDING DEXMEDETOMIDINE (DEXDOR) INTO THE LIST OF VITAL AND ESSENTIAL DRUGS

Abstract

Analysis of four pharmacoeconomic replacement models for midazolam, propofol and phentanyl with dexmedetomidine for sedation in resuscitation and intensive care unit (RICU) shows increase of the annual costs (at current prices) by 14-28 million rubles (at prices of the reference country – by 9-23 million rubles). The calculation of the RICU stay cost in the rates of the health care providers rather than in that of the Compulsory Health Insurance (CHI) effects a saving of up to 1 billion rubles at current prices and up to 3.5 billion rubles at prices of the reference country.

Keywords

• dexmedetomidine
• sedation in ricu
• pharmaco-economic analysis
• budget costs
• cost reimbursement